{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:54Z","timestamp":1792425354973,"version":"4.5.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Biologics have revolutionized the treatment of rheumatoid arthritis (RA) in recent years. However, data from clinical trials and actual clinical practice have shown that biologics currently in use may constitute a risk factor for reactivation of tuberculosis (TB) in patients with latent TB infection. Therefore, screening for latent and active TB infection is mandatory before initiating biologic therapy in patients with RA. This prospective study aimed to analyze the clinical characteristics of patients with RA receiving biologic disease-modifying antirheumatic drugs at Bach Mai Hospital, Vietnam, between 2017 and 2022, and to identify factors affecting the occurrence of active and latent TB infection among these patients. Over a 12-month follow-up period, latent TB infection was confirmed in 20% of the total 180 included patients, while 3 (1.7%) patients developed active TB (one case of pulmonary, pleural, and gluteal TB each). History of TB risk factor exposure and lack of education were significantly associated with the occurrence of active and latent TB infection, with odds ratios (95% confidence intervals [CIs]) of 1.98 (1.78; 2.2) and 1.45 (1.31; 1.6), respectively. Follow-up duration and number of X-ray, computed tomography, bronchoscopy, and sputum acid-fast bacteria examinations were identified as factors that can aid in the early diagnosis of latent TB, with odds ratios (95% CIs) of 1.00 (1; 1.01), 1.02 (1; 1.05), 1.12 (1.11; 1.2), 1.11 (1.09; 1.2), and 1.13 (1.09; 1.17), respectively. Our study showed that, in countries with high TB burden like Vietnam, latent TB infection has high prevalence among patients with RA. We also provide useful information for the screening, monitoring, and treatment of latent and active TB infection in patients with RA.<\/jats:p>","DOI":"10.1371\/journal.pone.0295048","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T18:25:04Z","timestamp":1704997504000},"page":"e0295048","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study"],"prefix":"10.1371","volume":"19","author":[{"given":"Binh Bui","family":"Hai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan Le","family":"Anh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-0852","authenticated-orcid":true,"given":"Phuong Nguyen","family":"Thi Thu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Nguyen","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giap Vu","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7614-9896","authenticated-orcid":true,"given":"Dung Hoang","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"2","key":"pone.0295048.ref001","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-857X(05)70201-5","article-title":"The epidemiology of rheumatoid arthritis","volume":"27","author":"SE Gabriel","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 3(","key":"pone.0295048.ref002","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1186\/ar578","article-title":"Epidemiology and genetics of rheumatoid arthritis","volume":"4","author":"AJ Silman","year":"2002","journal-title":"Arthritis Res"},{"issue":"3","key":"pone.0295048.ref003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review","volume":"36","author":"Y Alamanos","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"pone.0295048.ref004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"5","key":"pone.0295048.ref005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/27.5.341","article-title":"The 1987 revised American Rheumatism Association criteria for rheumatoid arthritis","volume":"27","author":"AJ Silman","year":"1988","journal-title":"Br J Rheumatol"},{"issue":"9","key":"pone.0295048.ref006","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"D Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"pone.0295048.ref007","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"L Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"pone.0295048.ref008","doi-asserted-by":"crossref","first-page":"845496","DOI":"10.1155\/2011\/845496","article-title":"Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature","volume":"2011","author":"M Benucci","year":"2011","journal-title":"Int J Rheumatol"},{"issue":"3","key":"pone.0295048.ref009","doi-asserted-by":"crossref","first-page":"e0119683","DOI":"10.1371\/journal.pone.0119683","article-title":"The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.","volume":"10","author":"JT Joensuu","year":"2015","journal-title":"PLoS One."},{"issue":"6","key":"pone.0295048.ref010","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pone.0295048.ref011","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.","volume":"2016","author":"GS Hazlewood","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"9914","key":"pone.0295048.ref012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"JS Smolen","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"pone.0295048.ref013","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"MK Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"6","key":"pone.0295048.ref014","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"F Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"pone.0295048.ref015","author":"Organization GWH","year":"2018","journal-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management"},{"issue":"Suppl 1","key":"pone.0295048.ref016","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00586-005-1044-x","article-title":"Pain assessment.","volume":"15","author":"M Haefeli","year":"2006","journal-title":"Eur Spine J"},{"issue":"4","key":"pone.0295048.ref017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria.","volume":"35","author":"J Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am."},{"issue":"6","key":"pone.0295048.ref018","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.","volume":"68","author":"G Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9877","key":"pone.0295048.ref019","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.","volume":"381","author":"C Gabay","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"pone.0295048.ref020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"G Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pone.0295048.ref021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5114\/reum.2018.77974","article-title":"Comorbidities in rheumatic arthritis.","volume":"56","author":"L Klodzinski","year":"2018","journal-title":"Reumatologia."},{"key":"pone.0295048.ref022","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s41927-020-00161-4","article-title":"Factors associated with disability in patients with rheumatoid arthritis with persistent moderate disease activity: a retrospective cohort study.","volume":"4","author":"IC Scott","year":"2020","journal-title":"BMC Rheumatol"},{"issue":"6","key":"pone.0295048.ref023","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/kew004","article-title":"Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts.","volume":"55","author":"L Carpenter","year":"2016","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"pone.0295048.ref024","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2012-201517","article-title":"Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity","volume":"72","author":"D Aletaha","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0295048.ref025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/rheumatology\/keh446","article-title":"Prospects for B-cell-targeted therapy in autoimmune disease.","volume":"44","author":"JC Edwards","year":"2005","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"pone.0295048.ref026","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.","volume":"19","author":"T Takeuchi","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"pone.0295048.ref027","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/39.9.975","article-title":"Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.","volume":"39","author":"A Maetzel","year":"2000","journal-title":"Rheumatology (Oxford)."},{"issue":"9313","key":"pone.0295048.ref028","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"HK Choi","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"pone.0295048.ref029","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","article-title":"The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment","volume":"54","author":"FC Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"22","key":"pone.0295048.ref030","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","article-title":"A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis","volume":"343","author":"JM Bathon","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0295048.ref031","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1529-0131(200110)45:5<462::AID-ART366>3.0.CO;2-V","article-title":"Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis","volume":"45","author":"DL Conn","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"7134","key":"pone.0295048.ref032","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/bmj.316.7134.811","article-title":"Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis","volume":"316","author":"PC Gotzsche","year":"1998","journal-title":"BMJ"},{"issue":"12","key":"pone.0295048.ref033","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"MK Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"key":"pone.0295048.ref034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2019.07.004","article-title":"Diagnosis and management of latent tuberculosis infection in Asia: Review of current status and challenges","volume":"87","author":"NI Paton","year":"2019","journal-title":"Int J Infect Dis"},{"key":"pone.0295048.ref035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2334-7-122","article-title":"Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease","volume":"7","author":"IM Adetifa","year":"2007","journal-title":"The Gambia. BMC Infect Dis"},{"issue":"2","key":"pone.0295048.ref036","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/427030","article-title":"Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model","volume":"40","author":"PC Hill","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0295048.ref037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"JA Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"pone.0295048.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.","volume":"69","author":"TR Sterling","year":"2020","journal-title":"MMWR Recomm Rep."},{"issue":"23","key":"pone.0295048.ref039","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"TR Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0295048.ref040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.therap.2017.02.002","article-title":"Latent tuberculosis infection screening prior to biological treatment in Tunisian patients","volume":"72","author":"M Slouma","year":"2017","journal-title":"Therapie"},{"issue":"9","key":"pone.0295048.ref041","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10067-008-0867-3","article-title":"The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients.","volume":"27","author":"I Hanta","year":"2008","journal-title":"Clin Rheumatol."},{"issue":"1","key":"pone.0295048.ref042","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO\u2019s Global Tuberculosis Report 2022.","volume":"4","author":"S. Bagcchi","year":"2023","journal-title":"Lancet Microbe."},{"issue":"1","key":"pone.0295048.ref043","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12879-018-3430-0","article-title":"Health seeking behaviour and delayed management of tuberculosis patients in rural Bangladesh","volume":"18","author":"K Ehsanul Huq","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0295048.ref044","doi-asserted-by":"crossref","first-page":"e0195409","DOI":"10.1371\/journal.pone.0195409","article-title":"Factors associated with tuberculosis treatment delay in patients co-infected with HIV in a high prevalence area in Brazil.","volume":"13","author":"BMF Nogueira","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"pone.0295048.ref045","doi-asserted-by":"crossref","first-page":"e0178035","DOI":"10.1371\/journal.pone.0178035","article-title":"The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan.","volume":"12","author":"CH Lim","year":"2017","journal-title":"PLoS One."},{"issue":"1\u20132","key":"pone.0295048.ref046","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9681(79)90012-2","article-title":"Bias in analytic research.","volume":"32","author":"DL Sackett","year":"1979","journal-title":"J Chronic Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T18:25:46Z","timestamp":1704997546000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295048"}},"subtitle":[],"editor":[{"given":"Ryu","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295048","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}